{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T19:41:02Z","timestamp":1783539662936,"version":"3.55.0"},"reference-count":101,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T00:00:00Z","timestamp":1592438400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.gastrohep.2020.04.006","type":"journal-article","created":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T02:54:58Z","timestamp":1597892098000},"page":"51-66","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Recomendaciones del Grupo Espa\u00f1ol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre el cribado y tratamiento de la infecci\u00f3n tuberculosa en pacientes con enfermedad inflamatoria intestinal"],"prefix":"10.1016","volume":"44","author":[{"given":"Sabino","family":"Riestra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Taxonera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamile","family":"Zabana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Carpio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bel\u00e9n","family":"Beltr\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00edriam","family":"Ma\u00f1osa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Barreiro-de Acosta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gastrohep.2020.04.006_bib0510","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor \u03b1-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0515","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0210-5705(03)70338-0","article-title":"Grupo Espa\u00f1ol de Trabajo de Enfermedad de Crohn y Colitis Ulcerosa (GETECCU). Consensus guideline on tuberculosis and treatment of inflammatory bowel disease with infliximab","volume":"26","author":"Obrador","year":"2003","journal-title":"Gastroenterol Hepatol."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0520","first-page":"109","article-title":"Recomendaciones del Grupo Espa\u00f1ol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre el cribado y tratamiento de la tuberculosis latente en pacientes con enfermedad inflamatoria intestinal","volume":"14","author":"Riestra","year":"2015","journal-title":"Enferm Inflam Intest Dia."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0525","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.cmi.2017.12.025","volume":"24","author":"Baddley","year":"2018","journal-title":"Clin Microbiol Infect."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0530","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.cmi.2018.02.002","volume":"24","author":"Winthrop","year":"2018","journal-title":"Clin Microbiol Infect."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0535","article-title":"ERS\/ECDC Statement: European Union standards for tuberculosis care, 2017 update","volume":"51","author":"Migliori","year":"2018","journal-title":"Eur Respir J."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0540","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/cid\/ciw778","article-title":"Official American Thoracic Society\/Infectious Diseases Society of America\/Centers for Disease Control and Prevention Clinical Practice Guidelines: diagnosis of tuberculosis in adults and children","volume":"64","author":"Lewinsohn","year":"2017","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0545","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1183\/13993003.01245-2015","article-title":"Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries","volume":"46","author":"Getahun","year":"2015","journal-title":"Eur Resp J."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0550","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/1756-185X.13129","article-title":"Tuberculosis and biologics in rheumatology: A special situation","volume":"20","author":"Handa","year":"2017","journal-title":"Int J Rheum Dis."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0555","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.autrev.2015.01.011","article-title":"Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice","volume":"14","author":"Cantini","year":"2015","journal-title":"Autoim Rev."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0560","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/1756-185X.12754","article-title":"APLAR rheumatoid arthritis treatment recommendations","volume":"18","author":"Lau","year":"2015","journal-title":"Int J Rheum Dis."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0565","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1177\/1203475418811347","article-title":"Practical guidelines for managing patients with psoriasis on biologics: an update","volume":"23","author":"Poelman","year":"2019","journal-title":"J Cutan Med Surg."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0570","first-page":"584","article-title":"Prevention and treatment of tuberculosis infection in candidates for biologic therapy: A multidisciplinary consensus statement adapted to the dermatology patient","volume":"109","author":"Rodriguez-Jim\u00e9nez","year":"2018","journal-title":"Actas Dermosifiliogr."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0575","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/bjd.15665","article-title":"British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017","volume":"177","author":"Smith","year":"2017","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0580","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1440-1843.2010.01739.x","article-title":"The immunology of tuberculosis: From bench to bedside","volume":"15","author":"Dheda","year":"2010","journal-title":"Respirology."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0585","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1016\/S0140-6736(19)30308-3","article-title":"Tuberculosis","volume":"393","author":"Furin","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0590","unstructured":"Centro Nacional de Epidemiolog\u00eda. Instituto de Salud Carlos III. Tuberculosis: vigilancia 2012 a 2017. Resultados de la Red Nacional de Vigilancia Epidemiol\u00f3gica. Disponible en: https:\/\/www.isciii.es\/QueHacemos\/Servicios\/VigilanciaSaludPublicaRENAVE\/EnfermedadesTransmisibles\/Documents\/INFORMES\/OTROS%20INFORMES\/RENAVE_vigilancia_TB_2017.pdf#search=tuberculosis"},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0595","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/ibd.20496","article-title":"Tuberculous chemoprophylaxis requirements and safety in inflammatory bowel disease patients prior to anti-TNF therapy","volume":"14","author":"Zabana","year":"2008","journal-title":"Inflamm Bowel Dis."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0600","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/01.MIB.0000438429.38423.62","article-title":"T-cell profiling and the immunodiagnosis of latent tuberculosis infection in patients with inflammatory bowel disease","volume":"20","author":"Arias-Guill\u00e9n","year":"2014","journal-title":"Inflamm Bowel Dis."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0605","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1038\/ajg.2009.322","article-title":"Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease","volume":"104","author":"Marehbian","year":"2009","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0610","doi-asserted-by":"crossref","first-page":"547","DOI":"10.3109\/07853890.2014.941919","article-title":"Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: A systematic review of randomized controlled trials","volume":"46","author":"Lorenzetti","year":"2014","journal-title":"Ann Med."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0615","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1093\/ecco-jcc\/jjz013","article-title":"Relevant Infections in Inflammatory Bowel Disease, and Their Relationship With Immunosuppressive Therapy and Their Effects on Disease Mortality","volume":"13","author":"Zabana","year":"2019","journal-title":"J Crohns Colitis."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0620","doi-asserted-by":"crossref","first-page":"S596","DOI":"10.1016\/S0016-5085(17)32134-0","article-title":"Comparison of rates of active tuberculosis infection in the phase 2 and 3 clinical trial programs for Anti-IL12\/23 and Anti-TNFs","volume":"152","author":"Loftus","year":"2017","journal-title":"Gastroenterology."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0625","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1093\/ibd\/izy153","article-title":"Low frequency of opportunistic infections in patients receiving vedolizumab in clinical trials and post-marketing setting","volume":"24","author":"Ng","year":"2018","journal-title":"Inflamm Bowel Dis."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0630","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1093\/infdis\/jis269","article-title":"Risk of tuberculosis reactivation with tofacitinib (CP-690550)","volume":"205","author":"Maiga","year":"2012","journal-title":"J Infect Dis."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0635","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1136\/annrheumdis-2015-207319","article-title":"Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis","volume":"75","author":"Winthrop","year":"2016","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0640","doi-asserted-by":"crossref","first-page":"541","DOI":"10.17235\/reed.2016.4440\/2016","article-title":"Risk factors for tuberculosis in inflammatory bowel disease: anti-tumor necrosis factor and hospitalization","volume":"108","author":"Riestra","year":"2016","journal-title":"Rev Esp Enferm Dig."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0645","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/apt.14926","article-title":"Risk of serious infection in healthcare workers with inflammatory bowel disease: a case-control study of the Groupe d\u2019Etude Th\u00e9rapeutique des Affections Inflammatoires du tube Digestif (GETAID)","volume":"48","author":"Gagni\u00e8re","year":"2018","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0650","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.crohns.2013.12.013","article-title":"Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease","volume":"8","author":"Rahier","year":"2014","journal-title":"J Crohns Colitis."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0655","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz313","article-title":"Radiological signs of latent tuberculosis on chest radiography: a systematic review and meta-analysis","volume":"6","author":"Uzorka","year":"2019","journal-title":"Open Forum Infect Dis."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0660","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.5588\/ijtld.12.0111","article-title":"Screening for latent tuberculosis in anti-TNF-\u03b1 candidate patients in a high tuberculosis incidence setting","volume":"16","author":"Saidenberg-Kermanac\u2019h","year":"2012","journal-title":"Int J Tuberc Lung Dis."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0665","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.eimc.2017.11.014","article-title":"Diagnosis and therapeutic approach of latent tuberculosis infection","volume":"36","author":"Dom\u00ednguez","year":"2018","journal-title":"Enferm Infecc Microbiol Clin."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0670","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.eimc.2017.10.010","article-title":"Sequential strategy for the LTBI screening of newly-arrived immigrants in vulnerable social situations","volume":"36","author":"Serre-Delcor","year":"2018","journal-title":"Enferm Infecc Microbiol Clin."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0675","first-page":"1192","article-title":"False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria?","volume":"10","author":"Farhat","year":"2006","journal-title":"Int J Tuberc Lung Dis."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0680","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.trstmh.2005.03.001","article-title":"Tuberculin reactivity in adults after 50 years of universal bacille Calmette-Guerin vaccination in Taiwan","volume":"99","author":"Yeh","year":"2005","journal-title":"Trans R Soc Trop Med Hyg."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0685","first-page":"1","article-title":"Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010","volume":"59","author":"Mazurek","year":"2010","journal-title":"MMWE Recomm Rep."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0690","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.3899\/jrheum.090173","article-title":"Purified protein derivative response in juvenile idiopathic arthritis","volume":"36","author":"Kiray","year":"2009","journal-title":"J Rheumatol."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0695","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S1542-3565(04)00060-6","article-title":"High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy","volume":"2","author":"Mow","year":"2004","journal-title":"Clin Gastroenterol Hepatol."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0700","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1136\/thoraxjnl-2015-207811","article-title":"Effect of immunosuppressive therapy on interferon \u03b3 release assay for latent tuberculosis screening in patients with autoimmune diseases: a systematic review and meta-analysis","volume":"71","author":"Wong","year":"2016","journal-title":"Thorax."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0705","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1093\/ecco-jcc\/jjx022","article-title":"Early tuberculin skin test for the diagnosis of latent tuberculosis infection in patients with inflammatory Bowel disease","volume":"11","author":"Taxonera","year":"2017","journal-title":"J Crohns Colitis."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0710","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/s11684-017-0573-0","article-title":"Testing of tuberculosis infection among Chinese adolescents born after terminating the Bacillus Calmette-Guerin booster vaccination: subgroup analysis of a population-based cross-sectional study","volume":"11","author":"Li","year":"2017","journal-title":"Front Med."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0715","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/ecco-jcc\/jjw022","article-title":"Tuberculosis in anti-tumour necrosis factor treated inflammatory bowel disease patients after the implementation of preventive measures: Compliance with recommendations and safety of retreatment","volume":"10","author":"Carpio","year":"2016","journal-title":"J Crohns Colitis."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0720","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01267-2017","article-title":"Frequency and significance of indeterminate and borderline Quantiferon Gold TB IGRA results","volume":"50","author":"Brown","year":"2017","journal-title":"Eur Respir J."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0725","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1016\/j.cgh.2017.11.038","article-title":"Factors That Contribute to Indeterminate Results From the QuantiFERON-TB Gold In-Tube Test in Patients With Inflammatory Bowel Disease","volume":"16","author":"Kaur","year":"2018","journal-title":"Clin Gastroenterol Hepatol."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0730","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1136\/annrheumdis-2011-200408","article-title":"Influence of replacing tuberculin skin test with ex vivo interferon gamma release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy","volume":"71","author":"Mariette","year":"2012","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0735","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0189202","article-title":"Immune-mediated inflammatory diseases differently affect;1; IGRAs\u2019 accuracy for latent tuberculosis infection diagnosis in clinical practice","volume":"12","author":"Latorre","year":"2017","journal-title":"PLoS One."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0740","doi-asserted-by":"crossref","first-page":"R114","DOI":"10.1186\/ar1994","article-title":"Inhibition of antituberculosis T-lymphocyte function with tumour necrosis factor antagonists","volume":"8","author":"Hamdi","year":"2006","journal-title":"Arthritis Res Ther."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0745","doi-asserted-by":"crossref","first-page":"e8517","DOI":"10.1371\/journal.pone.0008517","article-title":"Within-subject variability of Interferon-G assay results for tuberculosis and boosting effect of tuberculin skin testing: a systematic review","volume":"4","author":"van Zyl-Smit","year":"2009","journal-title":"PLoS One."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0750","doi-asserted-by":"crossref","first-page":"e97366","DOI":"10.1371\/journal.pone.0097366","article-title":"Tuberculin skin testing and treatment modulates interferon-gamma release assay results for latent tuberculosis in migrants","volume":"9","author":"O'Shea","year":"2014","journal-title":"PLoS One."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0755","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1164\/rccm.201704-0817OC","article-title":"Optimization and Interpretation of Serial QuantiFERON Testing to Measure Acquisition of Mycobacterium tuberculosis Infection","volume":"196","author":"Nemes","year":"2017","journal-title":"Am J Respir Crit Care Med."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0760","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1183\/09031936.00151309","article-title":"Tuberculosis treatment effect on T-cell interferon-gamma responses to Mycobacterium tuberculosis-specific antigens","volume":"36","author":"Chee","year":"2010","journal-title":"Eur Respir J."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0765","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/1471-2334-9-182","article-title":"New tools for detecting latent tuberculosis infection: Evaluation of RD1-specific long-term response","volume":"9","author":"Butera","year":"2009","journal-title":"BMC Infect Dis."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0770","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1111\/j.1572-0241.2008.02050.x","article-title":"Comparison of interferon-gamma release assay versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease","volume":"103","author":"Schoepfer","year":"2008","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0775","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1002\/ibd.21605","article-title":"Prednisolone treatment affects the performance of the QuantiFERON gold in-tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection","volume":"17","author":"B\u00e9lard","year":"2011","journal-title":"Inflamm Bowel Dis."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0780","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/ibd.21427","article-title":"Factors impacting the results of interferon-\u03b3 release assay and tuberculin skin test in routine screening for latent tuberculosis in patients with inflammatory bowel diseases","volume":"17","author":"Papay","year":"2011","journal-title":"Inflamm Bowel Dis."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0785","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/ibd.21329","article-title":"QuantiFERON TB gold testing for tuberculosis screening in an inflammatory bowel disease cohort in the United States","volume":"17","author":"Qumseya","year":"2011","journal-title":"Inflamm Bowel Dis."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0790","first-page":"21","article-title":"Comparison of Quantiferon-TB Gold versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease patients","volume":"22","author":"Andrisani","year":"2013","journal-title":"J Gastrointestin Liver Dis."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0795","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1097\/MIB.0000000000000147","article-title":"Performance of interferon-gamma release assay for tuberculosis screening in inflammatory bowel disease patients","volume":"20","author":"Wong","year":"2014","journal-title":"Inflamm Bowel Dis."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0800","first-page":"241","article-title":"Latent tuberculosis screening tests and active tuberculosis infection rates in Turkish inflammatory bowel disease patients under anti-tumor necrosis factor therapy","volume":"28","author":"\u00c7eki\u00e7","year":"2015","journal-title":"Ann Gastroenterol."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0805","doi-asserted-by":"crossref","first-page":"467","DOI":"10.15403\/jgld.2014.1121.244.bcg","article-title":"Tuberculin Skin Test and Quantiferon in BCG Vaccinated. Immunosuppressed Patients with Moderate-to-Severe Inflammatory Bowel Disease","volume":"24","author":"Kurti","year":"2015","journal-title":"J Gastrointestin Liver Dis."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0810","doi-asserted-by":"crossref","first-page":"292","DOI":"10.5152\/tjg.2018.17162","article-title":"Screening for latent tuberculosis infection in patients with inflammatory bowel disease: Can interferon-gamma release assays replace the tuberculin skin test?","volume":"29","author":"Cabriada","year":"2018","journal-title":"Turk J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0815","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1007\/s10620-018-5178-1","article-title":"A Study of Optimal Screening for Latent Tuberculosis in Patients with Inflammatory Bowel Disease","volume":"63","author":"Al-Taweel","year":"2018","journal-title":"Dig Dis Sci."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0820","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1007\/s10620-019-5475-3","article-title":"Superiority of Interferon Gamma Assay Over Tuberculin Skin Test for Latent Tuberculosis in Inflammatory Bowel Disease Patients in Brazil","volume":"64","author":"Amorim","year":"2019","journal-title":"Dig Dis Sci."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0825","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1136\/annrheumdis-2012-201979","article-title":"You can\u2019t always get what you want, but if you try sometimes (with two tests-TST and IGRA-for tuberculosis) you get what you need","volume":"71","author":"Winthrop","year":"2012","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0830","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/jgh.14019","article-title":"Asian Organization for Crohn's and Colitis and Asian Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: Risk assessment","volume":"33","author":"Park","year":"2018","journal-title":"J Gastroenterol Hepatol."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0835","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1002\/art.34382","article-title":"Interferon- \u03b3 release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis","volume":"64","author":"Hsia","year":"2012","journal-title":"Arth Rheum."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0840","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1136\/annrheumdis-2011-200941","article-title":"Screening for latent tuberculosis infection: performance of tuberculin skin test and interferon-gamma release assays under real-life conditions","volume":"71","author":"Kleinert","year":"2012","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0845","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.arbres.2015.04.016","article-title":"Consensus Document on Prevention and Treatment of Tuberculosis in Patients for Biological Treatment","volume":"52","author":"Mir Viladrich","year":"2016","journal-title":"Arch Bronconeumol."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0850","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1093\/ecco-jcc\/jjw129","article-title":"Negative screening does not rule out the risk of tuberculosis in patients with inflammatory bowel disease undergoing anti-TNF treatment: a descriptive study on the GETAID cohort","volume":"10","author":"Abitbol","year":"2016","journal-title":"J Crohns Colitis."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0855","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1093\/ecco-jcc\/jjy104","article-title":"Serial Tuberculin Skin Tests Improve the Detection of Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease","volume":"12","author":"Taxonera","year":"2018","journal-title":"J Crohn's Colitis."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0860","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/ard.2005.040055","article-title":"Does anti-tumour necrosis factor alpha treatment modify the tuberculin PPD response?","volume":"65","author":"Joven","year":"2006","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0865","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s00296-010-1424-3","article-title":"TNF-alpha antagonist therapy modify the tuberculin skin test response","volume":"31","author":"Cagatay","year":"2011","journal-title":"Rheumatol Int."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0870","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/art.23705","article-title":"Effectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy","volume":"59","author":"Chen","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0875","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.3899\/jrheum.090150","article-title":"Positive conversion of tuberculin skin test and performance of interferon release assay to detect hidden tuberculosis infection during anti-tumor necrosis factor agent trial","volume":"36","author":"Park","year":"2009","journal-title":"J Rheumatol."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0880","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s10238-010-0123-4","article-title":"A T-cell-based enzyme-linked immunospot assay for tuberculosis screening in Chinese patients with rheumatic diseases receiving infliximab therapy","volume":"11","author":"Xie","year":"2011","journal-title":"Clin Exp Med."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0885","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.dld.2013.03.005","article-title":"How frequently do tuberculosis screening tests convert in inflammatory bowel disease patients on anti-tumour necrosis factor-alpha? A pilot study","volume":"45","author":"Bermejo","year":"2013","journal-title":"Dig Liver Dis."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0890","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1093\/ecco-jcc\/jjx080","article-title":"Serial tuberculosis screening in inflammatory bowel disease patients receiving anti-TNF\u03b1 therapy","volume":"11","author":"Abreu","year":"2017","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0895","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1093\/ecco-jcc\/jjy057","article-title":"A Prospective Study to Monitor for Tuberculosis During Anti-tumour Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease and Immune-mediated Inflammatory Diseases","volume":"12","author":"Lee","year":"2018","journal-title":"J Crohns Colitis."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0900","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/art.21043","article-title":"Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists","volume":"52","author":"Carmona","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0905","first-page":"847","article-title":"How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?","volume":"3","author":"Comstock","year":"1999","journal-title":"Int J Tuberc Lung Dis."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0910","doi-asserted-by":"crossref","first-page":"248","DOI":"10.7326\/M17-0609","article-title":"Treatment of latent tuberculosis infection: An updated network meta-analysis","volume":"167","author":"Zenner","year":"2017","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0915","first-page":"701","article-title":"Treatment completion in latent tuberculosis infection at specialist tuberculosis units in Spain","volume":"14","author":"Anibarro","year":"2010","journal-title":"Int J Tuberc Lung Dis."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0920","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3899\/jrheum.140101","article-title":"Diagnosis of latent tuberculosis and prevention of reactivation in rheumatic patients receiving biologic therapy: International recommendations","volume":"91","author":"Iannone","year":"2014","journal-title":"J Rheumatol Suppl."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0925","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1164\/rccm.200510-1666ST","article-title":"An official ATS statement: Hepatotoxicity of antituberculosis therapy","volume":"174","author":"Saukkonen","year":"2006","journal-title":"Am J Respir Crit Care Med."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0930","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1056\/NEJMoa1714283","article-title":"Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults","volume":"379","author":"Menzies","year":"2018","journal-title":"N Engl J Med."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0935","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1185\/03007995.2012.747952","article-title":"Update on rifampin, rifabutin, and rifapentine drug interactions","volume":"29","author":"Baciewicz","year":"2013","journal-title":"Curr Med Res Opin."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0940","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1086\/427802","article-title":"Short-Course Therapy with Rifampin plus Isoniazid. Compared with Standard Therapy with Isoniazid, for Latent Tuberculosis Infection: A Meta-analysis","volume":"40","author":"Ena","year":"2005","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0945","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.amepre.2018.04.030","article-title":"Isoniazid-Rifapentine for Latent Tuberculosis Infection: A Systematic Review and Meta-analysis","volume":"55","author":"Njie","year":"2018","journal-title":"Am J Prev Med."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0950","doi-asserted-by":"crossref","first-page":"2034950","DOI":"10.1155\/2019\/2034950","article-title":"Simultaneous Adalimumab and Antitubercular Treatment for Latent Tubercular Infection: An Experience from Nepal","volume":"2019","author":"Vaidya","year":"2019","journal-title":"Int J Rheumatol."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0955","doi-asserted-by":"crossref","first-page":"e486","DOI":"10.1016\/j.crohns.2013.03.004","article-title":"Tuberculosis in anti-TNF-\u03b1 treated patients remains a problem in countries with an intermediate incidence: Analysis of 25 patients matched with a control population","volume":"7","author":"Abreu","year":"2013","journal-title":"J Crohns Colitis."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0960","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/MEG.0000000000001403","article-title":"Inflammatory bowel disease and mycobacteria: How much can we trust isoniazid prophylaxis during antitumor necrosis factor therapy?","volume":"31","author":"Akyuz","year":"2019","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0965","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s40257-019-00432-y","article-title":"Active Tuberculosis in Patients with Psoriasis Receiving Biologic Therapy: A Systematic Review","volume":"20","author":"Snast","year":"2019","journal-title":"Am J Clin Dermatol."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0970","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/thx.2005.046797","article-title":"British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment","volume":"60","year":"2005","journal-title":"Thorax."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0975","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1086\/592695","article-title":"Therapeutic Use of Infliximab in Tuberculosis to Control Severe Paradoxical Reaction of the Brain and Lymph Nodes","volume":"47","author":"Blackmore","year":"2008","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0980","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1086\/598504","article-title":"Adalimumab Treatment of Life-Threatening Tuberculosis","volume":"48","author":"Wallis","year":"2009","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0985","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1086\/427941","article-title":"Paradoxical Response to Antituberculous Therapy in Infliximab-Treated Patients with Disseminated Tuberculosis","volume":"40","author":"Garcia Vidal","year":"2005","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0990","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/ecco-jcc\/jjv172","article-title":"Reintroduction of anti-TNF\u03b1 therapy after (or even during) anti-TNF\u03b1-associated tuberculosis in immune-mediated diseases","volume":"10","author":"Abreu","year":"2016","journal-title":"J Crohns Colitis."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib0995","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/art.24632","article-title":"Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French research axed on tolerance of biotherapies registry","volume":"60","author":"Tubach","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib1000","doi-asserted-by":"crossref","first-page":"249","DOI":"10.5588\/ijtld.13.0751","article-title":"Recurrence of active tuberculosis following resumption of anti-TNF-\u03b1 therapy in a patient with Crohn's disease","volume":"18","author":"Masi\u00e1","year":"2014","journal-title":"Int J Tuberc Lung Dis."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib1005","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3899\/jrheum.150177","article-title":"Characteristics predicting tuberculosis risk under tumor necrosis factor-\u03b1 inhibitors: Report from a large multicenter cohort with high background prevalence","volume":"43","author":"Kisacik","year":"2016","journal-title":"J Rheumatol."},{"key":"10.1016\/j.gastrohep.2020.04.006_bib1010","doi-asserted-by":"crossref","first-page":"e0153816","DOI":"10.1371\/journal.pone.0153816","article-title":"Safety of resuming tumor necrosis factor inhibitors in ankylosing spondylitis patients concomitant with the treatment of active tuberculosis: A retrospective nationwide registry of the Korean Society of spondyloarthritis research","volume":"11","author":"Kim","year":"2016","journal-title":"PLoS One."}],"container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S021057052030217X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S021057052030217X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T12:44:55Z","timestamp":1759322695000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S021057052030217X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":101,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S021057052030217X"],"URL":"https:\/\/doi.org\/10.1016\/j.gastrohep.2020.04.006","relation":{},"ISSN":["0210-5705"],"issn-type":[{"value":"0210-5705","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recomendaciones del Grupo Espa\u00f1ol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre el cribado y tratamiento de la infecci\u00f3n tuberculosa en pacientes con enfermedad inflamatoria intestinal","name":"articletitle","label":"Article Title"},{"value":"Gastroenterolog\u00eda y Hepatolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastrohep.2020.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}